Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.

Marcus L, Murphy R, Fox E, McCully C, Cruz R, Warren KE, Meyer T, McNiff E, Balis FM, Widemann BC.

Cancer Chemother Pharmacol. 2012 Jan;69(1):247-52. doi: 10.1007/s00280-011-1659-z. Epub 2011 Jun 26.

PMID:
21706317
2.

Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.

Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM.

Clin Cancer Res. 2005 Feb 15;11(4):1669-74.

3.

Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates.

Jacobs S, McCully CL, Murphy RF, Bacher J, Balis FM, Fox E.

Cancer Chemother Pharmacol. 2010 Apr;65(5):817-24. doi: 10.1007/s00280-009-1085-7. Epub 2009 Aug 7.

PMID:
19662415
4.

The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.

Kim A, McCully C, Cruz R, Cole DE, Fox E, Balis FM, Widemann BC.

Invest New Drugs. 2012 Apr;30(2):524-8. doi: 10.1007/s10637-010-9585-1. Epub 2010 Nov 12.

PMID:
21072558
5.

Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.

Akshintala S, Marcus L, Warren KE, Murphy RF, Sissung TM, Srivastava A, Goodspeed WJ, Goodwin A, Brewer CC, Zalewski C, King KA, Kim A, Figg WD, Widemann BC.

Pediatr Blood Cancer. 2015 Apr;62(4):603-10. doi: 10.1002/pbc.25344. Epub 2015 Jan 3.

6.

The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.

Meany HJ, Fox E, McCully C, Tucker C, Balis FM.

Cancer Chemother Pharmacol. 2008 Aug;62(3):387-92. Epub 2007 Oct 12.

PMID:
17932674
7.

cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.

Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.

Clin Cancer Res. 1997 Nov;3(11):2063-74.

8.

Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.

Stapleton SL, Thompson PA, Ou CN, Berg SL, McGuffey L, Gibson B, Blaney SM.

Cancer Chemother Pharmacol. 2008 Apr;61(4):647-52. Epub 2007 May 31.

PMID:
17541590
9.

Evaluation of satraplatin in dogs with spontaneously occurring malignant tumors.

Selting KA, Wang X, Gustafson DL, Henry CJ, Villamil JA, McCaw DL, Tate D, Beittenmiller M, Garnett C, Robertson JD.

J Vet Intern Med. 2011 Jul-Aug;25(4):909-15. doi: 10.1111/j.1939-1676.2011.0727.x. Epub 2011 May 12.

10.

Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.

Ricart AD, Sarantopoulos J, Calvo E, Chu QS, Greene D, Nathan FE, Petrone ME, Tolcher AW, Papadopoulos KP.

Clin Cancer Res. 2009 Jun 1;15(11):3866-71. doi: 10.1158/1078-0432.CCR-08-2373. Epub 2009 May 19.

11.

Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.

Warren KE, McCully C, Dvinge H, Tjørnelund J, Sehested M, Lichenstein HS, Balis FM.

Cancer Chemother Pharmacol. 2008 Aug;62(3):433-7. Epub 2007 Oct 25.

PMID:
17960383
12.

Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy.

Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D, Hong DS, Oh WK, Bajorin DF.

Clin Genitourin Cancer. 2011 Sep;9(1):27-30. doi: 10.1016/j.clgc.2011.05.003. Epub 2011 Jun 22.

PMID:
21700509
13.

Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates.

Cho SY, Fox E, McCully C, Bauch J, Marsh K, Balis FM.

Cancer Chemother Pharmacol. 2007 Sep;60(4):563-7. Epub 2006 Dec 23.

PMID:
17187251
14.

Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates.

Muscal JA, Sun Y, Nuchtern JG, Dauser RC, McGuffey LH, Gibson BW, Berg SL.

Cancer Chemother Pharmacol. 2012 Apr;69(4):943-7. doi: 10.1007/s00280-011-1781-y. Epub 2011 Nov 23.

15.

Satraplatin: an orally available platinum analog for the treatment of cancer.

Choy H.

Expert Rev Anticancer Ther. 2006 Jul;6(7):973-82. Review.

PMID:
16831070
16.

Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate.

Riva L, Blaney SM, Dauser R, Nuchtern JG, Durfee J, McGuffey L, Berg SL.

Clin Cancer Res. 2000 Mar;6(3):994-7.

17.

Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model.

Cole DE, Lester-McCully CM, Widemann BC, Warren KE.

Cancer Chemother Pharmacol. 2015 May;75(5):923-8. doi: 10.1007/s00280-015-2711-1. Epub 2015 Mar 5.

PMID:
25740692
18.

Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.

Vouillamoz-Lorenz S, Buclin T, Lejeune F, Bauer J, Leyvraz S, Decosterd LA.

Anticancer Res. 2003 May-Jun;23(3C):2757-65.

PMID:
12926110
19.

Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.

Figg WD, Christian MC, Lush R, Link CJ, Davis P, Kohn E, Sarosy G, Rothenberg ML, Weiss RB, Ryan N, Jacobs J, Reed E.

Biopharm Drug Dispos. 1997 May;18(4):347-59.

PMID:
9158882
20.

Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.

Berg SL, Stone J, Xiao JJ, Chan KK, Nuchtern J, Dauser R, McGuffey L, Thompson P, Blaney SM.

Cancer Chemother Pharmacol. 2004 Jul;54(1):85-8. Epub 2004 Mar 23.

PMID:
15042312

Supplemental Content

Support Center